about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroGenomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review.JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.Philadelphia-negative chronic myeloproliferative neoplasmsThrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Molecular classification of myeloproliferative neoplasms-pros and cons.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review.Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy.Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Equivalence of BCSH and WHO diagnostic criteria for ET.Guideline for the diagnosis and management of myelofibrosis.Does thrombocyte size give us an idea about thrombocytosis etiology?Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges
P2860
Q26775996-A633A1E5-07AA-40D6-85D9-F7B284391890Q30315531-F76A9807-F6EA-4563-B738-8EAFCCA33B88Q33699967-301A979B-C7E3-4016-9F32-25AA85C56CDDQ34293019-AD43307F-5210-40B0-BFC9-966F3D0BE204Q36283143-9A49093C-C527-4F97-8535-91F998577F32Q36452870-F762860D-036A-433A-9AAB-B3A872E37049Q37555785-1F7A2CC3-AFF0-478A-BA25-E9AC555C5A0DQ37715790-7BB4A92E-9508-411E-988D-D9B1AA060361Q38087202-A794AA07-652C-420A-8205-0E9B0EBEC998Q38148982-4B16EBBA-B6E6-4C48-B809-E45772C0A139Q38210664-7F1E78B7-0C14-4F55-8F14-958B496D67D5Q39174715-E3C77C82-F081-447D-8BE5-8637A9D12956Q41553988-B50F372F-C54D-4BCD-932D-932CAFBE3FB8Q42224651-D1CBE59A-AE6B-4E65-9DC7-56537A95B543Q44394903-F02A62CC-558B-486F-BC5D-2F4726DCA1D1Q46636672-1C3668B8-8C56-42B9-8B8C-7FBB5EE84ED3Q50213969-BD18A732-2B4A-4225-9812-F62CDB8CFC31Q50495964-34EE3FD5-D674-4DE3-A867-25B1F367FB0BQ54482191-7587A49B-DD17-422B-B6D5-3E56594443F8Q58787724-4ED336C5-6679-4918-AED6-93B74BE4F66B
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
How I treat essential thrombocythemia.
@ast
How I treat essential thrombocythemia.
@en
type
label
How I treat essential thrombocythemia.
@ast
How I treat essential thrombocythemia.
@en
prefLabel
How I treat essential thrombocythemia.
@ast
How I treat essential thrombocythemia.
@en
P2093
P2860
P1433
P1476
How I treat essential thrombocythemia.
@en
P2093
Anthony R Green
Peter J Campbell
Philip A Beer
Wendy N Erber
P2860
P304
P356
10.1182/BLOOD-2010-08-270033
P407
P577
2010-11-24T00:00:00Z